Myasthenia gravis is rarely fatal with modern treatment, but it remains a condition that can kill, and the risk is not evenly distributed across all patients. The most dangerous period tends to be the first one to two years after diagnosis, when the disease is at its most severe and unpredictable. Roughly 10 to 15 percent of all patients will experience a myasthenic crisis requiring mechanical ventilation at some point in their lives, and respiratory failure is the primary way this disease threatens life. How long someone lives with MG depends heavily on their antibody subtype, age at diagnosis, access to care, and how well they respond to treatment.
The First Two Years Are the Riskiest
A long-running study that followed nearly 2,000 patients with MG between 1940 and 2000 found that the most severe weakness and highest mortality both clustered in the first one to two years of the disease, after which many patients experienced improvement.1Wiley Online Library. Lifetime course of myasthenia gravis This pattern still holds today, although overall survival has improved dramatically compared to mid-20th-century outcomes. The early danger comes partly from delays in diagnosis, partly from the time it takes to find the right treatment combination, and partly because the immune attack on the neuromuscular junction can be especially aggressive before it’s brought under control.
Once patients survive the initial years and reach a stable treatment regimen, many live a normal or near-normal lifespan. But “near-normal” is not “identical,” and it’s worth understanding what continues to pose a threat over time.
How MG Actually Kills
The acute danger in MG is respiratory failure. The disease weakens the muscles you use to breathe, the diaphragm and intercostal muscles, and if that weakness becomes severe enough, you can’t move air in and out of your lungs without a ventilator. This event, called myasthenic crisis, is the classic life-threatening emergency in MG. About 10 to 15 percent of patients experience at least one crisis during their lifetime.2PubMed Central. Myasthenia gravis, respiratory function, and respiratory tract disease
Respiratory failure can also come from the other direction. Overtreatment with cholinesterase inhibitors, one of the mainstay medications for MG, can trigger what’s called cholinergic crisis, which also leads to breathing difficulties. Distinguishing between a myasthenic crisis (too little drug effect) and a cholinergic crisis (too much) is a genuine clinical challenge, and because respiratory failure can develop unpredictably, hospitalization is recommended for most patients experiencing an exacerbation.3PubMed Central. Myasthenia gravis: myasthenia vs. cholinergic crisis
Looking at the broader mortality picture, a Norwegian study examining causes of death in MG patients from 1951 to 2001 found that respiratory tract disease appeared on death certificates significantly more often than in the general population, at about 28 percent versus 21 percent.4PubMed Central. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001 A Swedish study looking at actual causes of death found that cancer was the most common (about 20 percent), followed by ischemic heart disease (about 13 percent), and MG itself accounted for roughly 11 percent of deaths.5PubMed. Mortality rates and causes of death in Swedish Myasthenia Gravis patients That means the disease itself directly causes only about one in nine deaths in MG patients, but it raises vulnerability to other causes, particularly respiratory infections and treatment-related complications.
Antibody Subtype Changes the Risk Profile
Not all MG is the same disease under the hood. Most patients have antibodies against the acetylcholine receptor (AChR), but a smaller group has antibodies against a protein called MuSK. This distinction matters a great deal for prognosis. MuSK MG tends to come on fast, hit the throat and face muscles hard, and trigger early respiratory crises.6PubMed Central. MuSK-Associated Myasthenia Gravis: Clinical Features and Management A clinical comparison found that MuSK-positive patients had a higher frequency of bulbar involvement and respiratory emergencies than AChR-positive or seronegative patients.7PubMed. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis
When MuSK-positive patients do land in crisis, they tend to stay there longer. One study found that MuSK patients who needed mechanical ventilation required it for an average of about 43 days, compared with roughly 17 days for AChR-positive patients in crisis. Their intensive care stays and total hospital stays were similarly extended.8PubMed Central. MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation Longer ventilation and longer ICU time both raise the risk of secondary complications like hospital-acquired pneumonia and blood clots, which compound the danger.
There’s also a small group of patients who are “seronegative,” meaning standard antibody tests come back negative. Their outcomes tend to resemble AChR-positive patients more closely than MuSK patients, but diagnosis can be delayed precisely because the usual blood tests don’t flag the disease.
What Triggers a Crisis
Myasthenic crises rarely come out of nowhere. Common triggers include infections (particularly respiratory infections), surgery, emotional stress, and critically, medications. A surprisingly long list of drugs can worsen MG or provoke a crisis. Immune checkpoint inhibitors used in cancer treatment can actually cause new-onset MG. Certain antibiotics, heart rhythm drugs, anesthetics, and neuromuscular blockers can impair the neuromuscular junction in ways that tip a stable MG patient into crisis.9PubMed Central. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update This is one of the practical reasons MG patients are advised to carry a medical alert card and ensure every prescribing physician knows about their diagnosis.
Age at Onset and Why It Matters
MG behaves differently depending on when it first appears. People diagnosed later in life, particularly after age 65, face a steeper challenge. They tend to present with more severe disease at the outset, including more life-threatening events at diagnosis.10PubMed Central. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset Elderly-onset patients are less likely to achieve complete remission and have worse outcomes when they experience exacerbations, including a higher risk of death.11PubMed Central. Diagnosis and evaluation of elderly-onset myasthenia gravis: A case report
A large study directly comparing outcomes by age at onset confirmed that patients with late-onset MG were less likely to achieve a good functional status than those with early-onset disease, with about 67 percent of late-onset patients reaching a good outcome compared with roughly 75 percent of early-onset patients. Late onset was independently associated with poorer results even after adjusting for other factors.12PubMed. Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis
Part of this is the disease itself, and part is that older patients tend to have other health problems, a weaker immune reserve, and less tolerance for the immunosuppressive medications that keep MG under control. The interplay between aging, infection susceptibility, and MG treatment creates a more precarious balance.
MG in Children
Juvenile MG, diagnosed before age 18, generally carries a more favorable outlook than adult-onset disease. Prepubertal children in particular tend to have isolated eye symptoms more often, and they have a higher probability of achieving remission.13PubMed Central. Juvenile myasthenia gravis: a paediatric perspective A Norwegian population study of juvenile MG found that the general outcome was favorable: about 57 percent of patients eventually became asymptomatic, and only four subjects in the entire cohort failed to attain clinical improvement. That said, myasthenic crisis was actually more frequent in the prepubertal-onset group, making close monitoring in the early disease period essential even in children.14PubMed. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort
The Thymoma Connection
About 10 to 15 percent of MG patients have a thymoma, a tumor of the thymus gland, and these patients face a distinctly worse prognosis. A study comparing thymoma-associated MG with non-thymoma MG found higher disease severity at multiple follow-up points. Treatment refractoriness and mortality were both significantly elevated, with the thymoma group having roughly double the odds of treatment failure and about 2.5 times the mortality risk.15PubMed. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis The elevated risk here comes from two directions: thymomas are themselves tumors that can be invasive, and the immune dysregulation they cause makes the MG harder to control.
How Thymectomy and Treatment Affect Survival
Surgical removal of the thymus, called thymectomy, has become a cornerstone of MG treatment for many patients, even those without a thymoma. The landmark MGTX trial, published in the New England Journal of Medicine, showed that patients who underwent thymectomy plus prednisone fared better than those on prednisone alone: fewer needed additional immunosuppressive drugs (17 percent versus 48 percent), and fewer required hospitalization for exacerbations (9 percent versus 37 percent).16PubMed. Randomized Trial of Thymectomy in Myasthenia Gravis
Thymectomy also appears to improve the chances of achieving complete stable remission. A more recent study found that thymectomy patients were roughly three times more likely to maintain complete stable remission than those treated conservatively, and this benefit was especially pronounced in early-onset MG and in patients with purely ocular symptoms.17PubMed. Thymectomy promotes maintained complete stable remission in myasthenia gravis Fewer exacerbations, fewer hospitalizations, and lower medication burden all translate indirectly into better survival, since each crisis episode and each year of heavy immunosuppression carries its own mortality risk.
For the roughly 10 to 20 percent of patients whose MG proves refractory to standard treatments, newer options exist. Rituximab, a drug that depletes certain immune cells, has shown promise in this population. A retrospective study of 21 refractory patients found that half achieved complete or near-complete remission after rituximab treatment.18Cureus. Clinical Outcomes of Rituximab Infusion Among Refractory Myasthenia Gravis Patients in the Philippines: A 10-Year Retrospective Study Newer targeted therapies, including complement inhibitors and FcRn blockers, have also shown real benefits. A meta-analysis of these newer drug classes found that the odds of meaningful improvement in daily function were more than doubled, while the risk of clinical worsening dropped by about 72 percent and the need for rescue therapy fell by nearly half.19PubMed. Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis
The Hidden Risks of Long-Term Treatment
Effective treatment keeps MG from killing you, but the treatments themselves introduce risks that accumulate over years. The immunosuppressive drugs that most MG patients rely on make them more susceptible to infections. This is not a small effect. A large real-world study comparing MG patients to matched controls in the general population found that serious infections occurred at a rate of about 53 per 1,000 person-years in MG patients versus roughly 31 in the general population. Infection-related death was about twice as common in the MG group.20PubMed Central. Analysis of infections and malignancy risks among patients with myasthenia gravis compared with matched controls in a US real-world setting The same study found a higher overall malignancy rate in MG patients as well.
Despite improvements in MG treatment, mortality in MG patients remains higher than in the general population, partly because the treatments that suppress the immune system to control the disease simultaneously open the door to infections, and those infections can themselves trigger MG exacerbations, creating a vicious cycle.21PubMed. Aging and infectious diseases in myasthenia gravis
Long-term use of azathioprine, one of the most commonly used immunosuppressants in MG, has been linked to blood cell abnormalities and, in patients treated for more than a decade, occasional malignancies including lung cancer.22PubMed Central. Long-Term Adverse Effects and Survival in Patients with Myasthenia Gravis Treated with Azathioprine: A Retrospective Cohort These are rare but serious complications, and they underscore why neurologists try to find the lowest effective dose and why newer, more targeted therapies are so promising: they may offer immune control with fewer collateral effects on the rest of the immune system.
Racial Disparities in Outcomes
Not everyone with MG faces the same odds. In the United States, Black patients with MG are hospitalized for crisis or exacerbation at roughly three times the rate of white patients, even after accounting for differences in age, sex, and disease severity.23PubMed Central. Understanding Racial and Ethnic Disparities in Myasthenia Gravis Outcomes: EXPLORE-MG Registry Experience The reasons are likely a mix of differences in disease biology, access to specialist care, insurance coverage, and the well-documented pattern of delayed diagnosis in minority populations. Whatever the underlying causes, the gap in outcomes is real and clinically significant, meaning that the general survival statistics for MG may overstate how well the disease is managed for certain groups.
Pregnancy and MG
MG during pregnancy is manageable but genuinely high-risk. A large study found that pregnant women with MG faced a dramatically elevated risk of acute respiratory failure, with odds about 14 times higher than in pregnant women without MG. Hospital stays were also significantly longer.24PubMed. Maternal and neonatal outcomes among pregnant women with myasthenia gravis MG symptoms can worsen, remain stable, or occasionally improve during pregnancy, and the unpredictability is part of what makes it dangerous.
Babies born to mothers with MG also face specific risks. A nationwide cohort study found elevated odds of low birthweight, feeding problems, and transfer to a neonatal unit. About 4 percent of babies developed transient neonatal MG, a temporary form of the disease caused by maternal antibodies crossing the placenta.25PubMed. Obstetric and Neonatal Outcomes in Patients With Maternal Myasthenia Gravis: A Nationwide Cohort Study In rare cases, maternal antibodies can cause more severe fetal effects.26PubMed Central. Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in Germany For these reasons, MG pregnancies are best managed at centers where neurology, obstetrics, anesthesia, and neonatology teams can coordinate closely.
Depression, Anxiety, and Their Effect on Outcomes
An often-overlooked threat to MG patients isn’t physical at all. Depression and anxiety are common in MG, more so than in many other autoimmune conditions.27PubMed Central. Prevalence of depression and anxiety among myasthenia gravis (MG) patients: A systematic review and meta-analysis This isn’t just about quality of life in the abstract. Depression in MG patients has been shown to negatively affect health-related quality of life beyond what the physical severity of the disease alone would predict, and it also increases the burden on caregivers.28PubMed Central. Mental health in myasthenia gravis patients and its impact on caregiver burden Depressed patients are less likely to adhere to complex medication regimens, less likely to seek care during early signs of exacerbation, and more likely to experience fatigue that compounds the muscle weakness already caused by the disease. Treating the mental health side of MG is not optional if the goal is keeping patients safe over the long term.
Thymectomy in Patients Without a Thymoma
One area where the evidence has shifted meaningfully in recent years is the question of whether MG patients without a thymoma should still have their thymus removed. For decades, thymectomy was considered primarily for patients with thymomas or young women with generalized AChR-positive disease. The MGTX trial changed that calculus by showing clear benefits of thymectomy in AChR-positive patients without thymoma.16PubMed. Randomized Trial of Thymectomy in Myasthenia Gravis A case-control study similarly concluded that thymectomy produced superior results compared with medical management alone and should be offered to AChR-antibody-positive patients as part of their treatment plan.29PubMed Central. Effect of Thymectomy on Outcomes of Myasthenia Gravis Patients: A Case-Control Study at a Tertiary Care Hospital Because fewer exacerbations mean fewer crises, and fewer crises mean lower mortality risk, the survival implications of this surgical shift are real, even though thymectomy is not itself a cure.
The benefit appears strongest in early-onset, AChR-positive patients. For MuSK-positive patients or those who are seronegative, the evidence for thymectomy is weaker, and management relies more heavily on immunosuppression and newer targeted drugs.